A ntitumor activity of sorafenib and imatinib in a patient with thymic carcinoma harboring c-KIT exon 13 missense mutation K642E

Chiara Catania, Fabio Conforti, Gianluca Spitaleri, Massimo Barberis, Lorenzo Preda, Cristina Noberasco, Chiara Lazzari, Francesca Toffalorio, Filippo de Marinis, Michela Manzotti, Tommaso Martino De Pas

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

We report the case of a man with an advanced nonkeratinizing squamous cell thymic carcinoma harboring c-KIT exon 13 missense mutation K642E. This aberration is rare and has never been described previously in patients with thymic cancers. It has been found in a small number of cases of gastrointestinal stromal tumor and also in several cases of acral and mucosal melanomas. Some of the patients with gastrointestinal stromal tumor or melanoma harboring this rare mutation have had a tumor response when treated with imatinib. In contrast, in our case, the mutation was associated with primary resistance to full doses of imatinib but, at the same time, it was not a cause of resistance to sorafenib.

Original languageEnglish
Pages (from-to)697-702
Number of pages6
JournalOncoTargets and Therapy
Volume7
DOIs
Publication statusPublished - May 8 2014

Fingerprint

Gastrointestinal Stromal Tumors
Thymoma
Missense Mutation
Exons
Melanoma
Thymus Neoplasms
Mutation
Squamous Cell Carcinoma
Extremities
Neoplasms
Imatinib Mesylate
sorafenib

Keywords

  • Imatinib
  • Sorafenib
  • Thymic carcinoma

ASJC Scopus subject areas

  • Oncology
  • Pharmacology (medical)

Cite this

@article{ae3f34d06dfe4a74b247dbfbf326bc97,
title = "A ntitumor activity of sorafenib and imatinib in a patient with thymic carcinoma harboring c-KIT exon 13 missense mutation K642E",
abstract = "We report the case of a man with an advanced nonkeratinizing squamous cell thymic carcinoma harboring c-KIT exon 13 missense mutation K642E. This aberration is rare and has never been described previously in patients with thymic cancers. It has been found in a small number of cases of gastrointestinal stromal tumor and also in several cases of acral and mucosal melanomas. Some of the patients with gastrointestinal stromal tumor or melanoma harboring this rare mutation have had a tumor response when treated with imatinib. In contrast, in our case, the mutation was associated with primary resistance to full doses of imatinib but, at the same time, it was not a cause of resistance to sorafenib.",
keywords = "Imatinib, Sorafenib, Thymic carcinoma",
author = "Chiara Catania and Fabio Conforti and Gianluca Spitaleri and Massimo Barberis and Lorenzo Preda and Cristina Noberasco and Chiara Lazzari and Francesca Toffalorio and {de Marinis}, Filippo and Michela Manzotti and {De Pas}, {Tommaso Martino}",
year = "2014",
month = "5",
day = "8",
doi = "10.2147/OTT.S58902",
language = "English",
volume = "7",
pages = "697--702",
journal = "OncoTargets and Therapy",
issn = "1178-6930",
publisher = "Dove Medical Press Ltd.",

}

TY - JOUR

T1 - A ntitumor activity of sorafenib and imatinib in a patient with thymic carcinoma harboring c-KIT exon 13 missense mutation K642E

AU - Catania, Chiara

AU - Conforti, Fabio

AU - Spitaleri, Gianluca

AU - Barberis, Massimo

AU - Preda, Lorenzo

AU - Noberasco, Cristina

AU - Lazzari, Chiara

AU - Toffalorio, Francesca

AU - de Marinis, Filippo

AU - Manzotti, Michela

AU - De Pas, Tommaso Martino

PY - 2014/5/8

Y1 - 2014/5/8

N2 - We report the case of a man with an advanced nonkeratinizing squamous cell thymic carcinoma harboring c-KIT exon 13 missense mutation K642E. This aberration is rare and has never been described previously in patients with thymic cancers. It has been found in a small number of cases of gastrointestinal stromal tumor and also in several cases of acral and mucosal melanomas. Some of the patients with gastrointestinal stromal tumor or melanoma harboring this rare mutation have had a tumor response when treated with imatinib. In contrast, in our case, the mutation was associated with primary resistance to full doses of imatinib but, at the same time, it was not a cause of resistance to sorafenib.

AB - We report the case of a man with an advanced nonkeratinizing squamous cell thymic carcinoma harboring c-KIT exon 13 missense mutation K642E. This aberration is rare and has never been described previously in patients with thymic cancers. It has been found in a small number of cases of gastrointestinal stromal tumor and also in several cases of acral and mucosal melanomas. Some of the patients with gastrointestinal stromal tumor or melanoma harboring this rare mutation have had a tumor response when treated with imatinib. In contrast, in our case, the mutation was associated with primary resistance to full doses of imatinib but, at the same time, it was not a cause of resistance to sorafenib.

KW - Imatinib

KW - Sorafenib

KW - Thymic carcinoma

UR - http://www.scopus.com/inward/record.url?scp=84900400930&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84900400930&partnerID=8YFLogxK

U2 - 10.2147/OTT.S58902

DO - 10.2147/OTT.S58902

M3 - Article

AN - SCOPUS:84900400930

VL - 7

SP - 697

EP - 702

JO - OncoTargets and Therapy

JF - OncoTargets and Therapy

SN - 1178-6930

ER -